| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short reports |
Department of Paediatrics, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
Correspondence to:
Dr C L Acerini, Department of Paediatrics, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, UK; cla22{at}cam.ac.uk
Accepted for publication 31 July 2007
 | ABSTRACT |
|---|
 TOP ABSTRACT METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Concordance with GH therapy has been related to patient and family education, timing and location of education sessions, and the type of healthcare professional providing the education.2 3 In a retrospective observational study we examined whether various differences in GH prescribing policies were associated with objectively measured treatment concordance and short-term growth outcomes.
| METHODS |
|---|
| TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
We sent a postal questionnaire to the children’s general practitioners (GPs) who issued the GH prescriptions under a shared care agreement. Data on 11 patients were obtained from an outreach clinic where GH prescriptions were provided directly by a designated local consultant paediatrician. The questionnaire requested details on the number of issued prescriptions and the total GH dose (or number of vials/cartridges) issued with each prescription during three specific 12-month periods (1999–2000, 2000–2001 and 2002–2003). Most of the data returned by GPs was in the form of computerised printouts. We approached 66 GP practices and 58 replied (response rate 88%).
GH devices used included automatic injection devices (n = 38), manual injection pen devices (n = 33) and needle-free injection devices (n = 4). According to a gradual change in clinic policy, children had been either allocated to a specific GH device by the nurse specialist or consultant, or had been offered a free choice of devices. All children and parents received training on GH delivery from one nurse specialist (SB). Patients were seen in the regional clinic every 4–6 months for assessment of height by the nurse specialists and review of GH doses.
Concordance
Concordance was objectively assessed in each child by comparing total expected GH usage as documented in the clinic records and letters to the total amount of GH prescribed by GPs during a 12-month period. From the expected daily dose (mg/day) (A), the expected annual GH requirement for each patient (B) was calculated. The number of issued prescriptions and the number of vials provided with each prescription enabled calculation of the total amount of GH prescribed by the GP over the same 12-month period (C). The annual deficit (D) in GH prescribed compared to that expected was calculated as (D = B–C). The estimated number of missed injections per week was calculated as (D/[52xA]).
Calculations and statistics
Height standard deviation scores (SDS) were calculated by comparison with the UK 1990 growth reference. Cross-sectional analysis was performed using the first data entry from each of the 75 children. Associations with concordance were tested by using 
2 trend tests for categorical variables (choice of GH device, prescription duration) and by linear regression for continuous variables (age, duration of treatment and height velocity).
Longitudinal analysis was performed using 71 data points, taken once every 2 years from 31 of the children (22 children provided two data points and nine children provided three data points). Longitudinal analyses between changes in concordance, prescription duration and height velocity were performed by analysis of co-variance by adding subject name as a fixed factor.
Finally, using all data points, chronological changes from 1999 to 2003 in concordance, prescription duration and height velocity were tested using 2 trend tests for categorical variables, and linear regression for continuous variables. Analyses were performed using SPSS version 11.0.
| RESULTS |
|---|
| TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
More than >1 injection/week was missed by 39% (29/75) of the children, and 23% (17/75) missed >2 injections/week. Table 1 shows that factors associated with lower concordance were a longer duration on GH therapy (p<0.005), lack of choice over GH device (p<0.005) and short duration (<4 weeks) of GH prescriptions (p<0.005). Concordance was unrelated to age or initial height SDS. Lower concordance was associated with reduced height velocity (p<0.005); this association remained significant after adjustment for duration of GH therapy (p<0.05; table 1), and the effect was particularly evident during the first 2 years of GH therapy (p<0.05; data not shown).
|
Longitudinal data analysis
A total of 31 children provided 71 repeated data points at intervals of 2 years between 1999 and 2003. In longitudinal within-individual analyses, prescription durations increased by (mean (SE)) 0.57 (0.21) weeks/year (p = 0.01). Avoidance of prescription durations of <4 weeks was associated with an increase of 1.12 (0.39) injections/week (p = 0.005) and a trend towards a rise in height velocity of 0.20 (0.13) SDS/year (p = 0.1).
Chronological analysis
Analyses of all 115 data points from the 75 children according to chronological year showed significant trends towards older age (but not longer duration of GH therapy), longer duration of prescriptions, improved concordance and increased growth responses to treatment (table 2).
|
| DISCUSSION |
|---|
| TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
However, these proportions are consistent with other studies using other objective assessments. From data on encashed prescriptions, Hunter et al found that 33% of their patients received less than 80% of their expected GH dose.1 Similarly, Desrosiers et al reported that 15–24% of 630 children missed more than three injections per month.4
The need for a long-term commitment to daily subcutaneous injections has major implications for the child and the family. In our study, decreasing concordance was associated with a longer duration on GH therapy. In recent years, a number of new injection delivery devices have been introduced which have simplified the drug administration process. However, in our study concordance did not differ between types of injection device. Rather, a free choice of injection device was associated with better concordance. One earlier study reported that choice of GH device had no effect on concordance.5 Those investigators studied the effect of a change in their clinic policy in 165 children. Interestingly, levels of concordance were already high (89%) in their group given no choice of device (before December 2000). However, in their study, patient satisfaction appeared to be higher in those patients who had been offered a choice of device.
We found that concordance was positively related to duration of the GH prescription given by the GP. Short GH prescription duration and consequently more frequent prescription collections and pharmacy visits could have an adverse impact on family routine and increase the risk of GH supplies running out before collection of the next prescription. Following interim analyses of our study in 2000/1, we gradually extended free choice of GH devices to all new patients, and also encouraged GPs to avoid short prescription durations. While these are uncontrolled observational data, these interventions appear to have helped to increase both concordance and growth responses.
In conclusion, objective assessment of prescription data in a regional clinic setting revealed a high prevalence of poor concordance with GH therapy. As in other studies, poor concordance was associated with a reduction in height velocity.1 4 Our study identified a number of factors which influenced concordance, including choice of GH injection device and GH prescription duration. Identification of these factors informed our interventions to improve concordance and treatment responses in our clinic.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
DBD, IAH, KO and CLA have either received research funding support and/or honoraria for speaking at meetings or have served on the advisory boards of one or more the following pharmaceutical companies who manufacture and sell human recombinant growth hormone: Novo Nordisk, Pfizer, Ipsen, Eli Lilly and Ferring.
Published Online First 31 August 2007
| REFERENCES |
|---|
| TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Relevant Article
This article has been cited by other articles:
|
|
 |
|
  Petrou and McIntosh Measuring the benefits of growth hormone therapy in children: a role for preference-based approaches? Arch. Dis. Child., February 1, 2008; 93(2): 95 - 97. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| ARCH DIS CHILD | FETAL NEONATAL ED | ED PRACTICE |
